 Monopar Therapeutics Inc. MNPR today announced it has been granted Orphan Drug Designation from the European Commission for its drug candidate camsirubicin in the treatment of soft tissue sarcoma STS, and the European Medicines Agencys Committee for Orphan Medicinal Products has issued its public summary of opinion for the designation, which can be found on the Companys website: Orphan Drug Designation: is given to medicinal products that represent a significant benefit over existing treatments; are intended for the treatment, prevention or diagnosis of a disease that is life-threatening or chronically debilitating; and where prevalence of the condition in the European Union EU is less than 5 in 10,000 persons. 